Fenwick Represents MRL Ventures in VectorY’s $138 Million Series A Financing

Fenwick represented MRL Ventures, the therapeutics-focused corporate venture fund of Merck & Co., in its investment in VectorY’s $138 million Series A financing, one of the largest private biotech financings in Europe in 2023. The round was co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund.

VectorY, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, will use the proceeds to support the clinical development of VTx-002, its lead vectorized antibody program targeting TDP-43 for the treatment of ALS. More information can be obtained from the company’s announcement.

The transaction was led by corporate partner Ian Goldstein and associates Serena Ward and Ty Chung.

Login

Don’t have an account yet?

Register